Author pages are created from data sourced from our academic publisher partnerships and public sources.
Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association
- P. Heidenreich, N. Albert, +11 authors J. Trogdon
- Medicine, Political Science
- Circulation. Heart failure
- 1 May 2013
Background—Heart failure (HF) is an important contributor to both the burden and cost of national healthcare expenditures, with more older Americans hospitalized for HF than for any other medical… Expand
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
- R. Bresalier, R. Sandler, +9 authors J. Baron
- The New England journal of medicine
- 17 March 2005
BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report… Expand
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
CONTEXT Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure. OBJECTIVE To investigate the effects of… Expand
Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.
- M. Konstam, Daniel G. Kramer, A. Patel, M. Maron, J. Udelson
- JACC. Cardiovascular imaging
Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those with… Expand
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.
Heart failure (HF) is a syndrome characterized by high mortality, frequent hospitalization, reduced quality of life, and a complex therapeutic regimen. Knowledge about HF is accumulating so rapidly… Expand
Acute Heart Failure Syndromes: Current State and Framework for Future Research
Acute heart failure syndromes (AHFS) poses unique diagnostic and management challenges. This syndrome has recently received attention from researchers, clinicians, regulatory agencies, and the… Expand
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
CONTEXT Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise… Expand
Heart failure: evaluation and care of patients with left ventricular systolic dysfunction.
Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)
Background—Combined inhibition of the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits in heart failure than ACE inhibition alone. Methods and… Expand
Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.
- A. Al-Ahmad, W. Rand, +4 authors M. Sarnak
- Journal of the American College of Cardiology
- 1 October 2001
OBJECTIVES We sought to evaluate the relationship between the level of kidney function, level of hematocrit and their interaction on all-cause mortality in patients with left ventricular (LV)… Expand